Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 9/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13073534 | 0.99 | TK2 (0.43) | TK2ALOX12TK1SLC6A1CYP2C9 | |
| SCHEMBL13073171 | 0.99 | TK2 (0.43) | TK2ALOX12TK1SLC6A1CYP2C9 | |
| SCHEMBL13073169 | 0.99 | TK2 (0.43) | TK2ALOX12TK1SLC6A1CYP2C9 | |
| SCHEMBL13073174 | 0.99 | TK2 (0.43) | TK2ALOX12TK1SLC6A1CYP2C9 | |
| SCHEMBL13073168 | 0.99 | TK2 (0.43) | TK2ALOX12TK1SLC6A1CYP2C9 | |
| SCHEMBL13073130 | 0.97 | TK2 (0.40) | TK2ALOX12TK1SLC6A1CYP2C9 | |
| SCHEMBL12340292 | 0.90 | SLC6A11 (0.44) | TK2SLC6A1KMT2ASLC6A11 | |
| SCHEMBL13073478 | 0.88 | DUT (0.40) | TK2ALOX12SLC6A1CYP2C9ALOX15 | |
| SCHEMBL13073640 | 0.85 | SLC6A1 (0.44) | TK2SLC6A1KMT2ASLC6A11 | |
| SCHEMBL13073476 | 0.83 | TK2 (0.40) | TK2TSHRDUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | TK2 4082/4885ALOX12 3789/4885TK1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.